University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Jay Reddy Publications

Veterinary and Biomedical Sciences, Department of

8-2013

Mimicry epitope from Ehrlichia canis for
interphotoreceptor retinoid-binding protein
201–216 prevents autoimmune uveoretinitis by
acting as altered peptide ligand
Arunakumar Gangaplara
University of Nebraska-Lincoln

Chandirasegaran Massilamany
University of Nebraska-Lincoln, cmassilamany@unl.edu

David Steffen
University of Nebraska-Lincoln, dsteffen1@unl.edu

Jay Reddy
University of Nebraska-Lincoln, jayreddy@unl.edu

Follow this and additional works at: http://digitalcommons.unl.edu/vbsjayreddy
Part of the Veterinary Microbiology and Immunobiology Commons
Gangaplara, Arunakumar; Massilamany, Chandirasegaran; Steffen, David; and Reddy, Jay, "Mimicry epitope from Ehrlichia canis for
interphotoreceptor retinoid-binding protein 201–216 prevents autoimmune uveoretinitis by acting as altered peptide ligand" (2013).
Jay Reddy Publications. 22.
http://digitalcommons.unl.edu/vbsjayreddy/22

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Jay Reddy Publications by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.

Published in Journal of Neuroimmunology 263: 1–2 (2013), pp. 98–107; doi: 10.1016/j.jneuroim.2013.08.006
Copyright © 2013 Elsevier B.V. Used by permission.
Submitted December 17, 2012; revised May 28, 2013; accepted August 12, 2013; published online August 17, 2013.
digitalcommons.unl.edu

Mimicry epitope from Ehrlichia canis for interphotoreceptor
retinoid-binding protein 201–216 prevents autoimmune
uveoretinitis by acting as altered peptide ligand
Arunakumar Gangaplara, Chandirasegaran Massilamany, David Steffen, and Jay Reddy
School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE 68583
Corresponding author — J. Reddy, Room 202, Bldg. VBS, School of Veterinary Medicine and Biomedical Sciences,
University of Nebraska-Lincoln, Lincoln, NE 68583; tel 402 472-8541, fax 402 472-9690, email nreddy2@unl.edu

Abstract
We report here identification of novel mimicry epitopes for interphotoreceptor retinoid-binding protein (IRBP) 201–216, a candidate ocular antigen that causes experimental autoimmune uveoretinitis (EAU) in A/J mice. One mimicry epitope from Ehrlichia canis (EHC), designated EHC 44–59, induced cross-reactive T cells for IRBP 201–216 capable of producing T helper (Th)1 and Th17
cytokines, but failed to induce EAU in A/J mice. In addition, animals first primed with suboptimal doses of IRBP 201–216 and subsequently immunized with EHC 44–59 did not develop EAU; rather, the mimicry epitope prevented the disease induced by IRBP
201–216. However, alteration in the composition of EHC 44–59 by substituting alanine with valine at position 49, similar to the
composition of IRBP 201–216, enabled the mimicry epitope to acquire uveitogenicity. The data provide new insights as to how microbes containing mimicry sequences for retinal antigens can prevent ocular inflammation by acting as naturally occurring altered
peptide ligands.
Keywords: Autoimmunity, Experimental autoimmune uveoretinitis, Molecular mimicry, Interphotoreceptor retinoid-binding protein, Cross-reactive T cells
Abbreviations:7-AAD, 7-aminoactinomycin D; APL, altered peptide ligand; CFA, complete Freund’s adjuvant; CLIP, class-II associated invariant chain peptide; CLN, Clostridium novyi; cpm, counts per minute; CTR, Chlamydia trachomatis; DELFIA, dissociationenhanced lanthanide fluoroimmunoassay; EAU, experimental autoimmune uveoretinitis; EHC, Ehrlichia canis; HEC, hepatitis C virus; HEL, hen egg white lysozyme; IRBP, interphotoreceptor retinoid-binding protein; IL, interleukin; IC50, half maximal inhibitory
concentration; IFN, interferon; LN, lymph nodes; LNC, lymph node cells; MHC, major histocompatibility complex; PAB, Paracoccidioides brasiliensis; PMA, phorbol 12-myristate 13-acetate; PSP, Pseudomonas putida; PT, pertussis toxin; RNase, bovine ribonuclease;
RT, room temperature; SA, streptavidin; TCR, T cell receptor; tet+, tetramer positive; TRC, Trypanosoma cruzi.

1. Introduction

al., 2000). In genetically susceptible individuals, such a pre-existing repertoire of self-reactive T cells can be activated to become
pathogenic cells, as might occur in response to exposure to infectious agents. This phenomenon may involve a combination of
mechanisms, such as bystander activation, release of cryptic epitopes, epitope spreading and molecular mimicry (Miller et al.,
1997b; Oldstone, 2005; Fujinami et al., 2006).
Molecular mimicry is a natural phenomenon in which microbes carrying sequences identical to those found in self-antigens
can lead to the generation of cross-reactive immune responses directed against both foreign and self-antigens (Fujinami and Oldstone, 1985; Fujinami et al., 2006). Several experimental examples
provide a proof-of-concept that the microbial mimics can break selftolerance and induce autoimmunity (Miller et al., 1997b; Oldstone,
2005; Fujinami et al., 2006). Conversely, pathogens that primarily
affect the target organs can lead to secondary generation of autoimmune responses by epitope spreading, as shown with Theiler’s murine encephalomyelitis virus-induced demyelination model in SJL
mice (Miller et al., 1997a; Olson et al., 2002). However, when a disease process involves both molecular mimicry and epitope spreading, the former generally precedes the latter.

The eye is generally considered an immunologically privileged
organ, and several mechanisms have been postulated to explain
this phenomenon (Streilein et al., 2002; Caspi, 2006; Vallochi et
al., 2007; Benhar et al., 2012). These include sequestration of antigens behind the blood–retinal barrier; lack of lymphatic drainage;
absence of professional antigen-presenting cells; and the existence
of an inherently bestowed immune-suppressive environment
through the production of cytokines like transforming growth
factor-β (Cousins et al., 1991; Hamrah and Dana, 2007; Forrester
and Xu, 2012). Because of sequestration, ocular antigens are not
expected to be recognized by the developing thymocytes, leading
to their escape from central tolerance. However, this notion is increasingly being challenged, following demonstration of the expression of various retinal antigens, like interphotoreceptor retinoid-binding protein (IRBP), and soluble antigens within the
thymus (Charukamnoetkanok et al., 1998; Takase et al., 2005).
Nonetheless, alterations in the amounts of protein expression can
still affect thymic education of T cells, leading to their safe exit
into the peripheral repertoires (Anderson et al., 2000; Klein et
98
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Our studies involve IRBP 201–216-induced experimental autoimmune uveoretinitis (EAU) in A/J mice. Using IRBP 201–216 as a
putative ocular antigen (Namba et al., 1998; Agarwal et al., 2012),
we searched for mimicry sequences from pathogens primarily affecting the eyes, with an expectation that such microbes can serve
as ideal candidates to delineate autoimmune events in the immune
pathogenesis of eye diseases. This search resulted in the identification of 48 novel sequences belonging to various classes of microbes.
One of these mimicry epitopes, derived from Ehrlichia canis (EHC)
and designated EHC 44–59, induces cross-reactive T cells for IRBP
201–216 capable of producing inflammatory cytokines of T helper
(Th)1 and Th17 subsets. Unexpectedly, EHC 44–59 failed to induce
EAU; rather, it prevented the development of disease induced by
IRBP 201–216, possibly by acting as a naturally occurring altered
peptide ligand (APL).
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2.3. Peptide synthesis

2. Materials and methods

Peptides synthesized commercially on 9-fluorenylmethyloxycarbonyl chemistry (Neopeptide, Cambridge, MA) include IRBP
201–216; EHC 44–59, HDKDVAVLASSRLSNR; Pseudomonas putida (PSP) 46–61, ADADALVLTRERTRID; Trypanosoma cruzi (TRC)
94–109, DDSDVVVLTSENVEKS; Clostridium novyi (CLN) 14–29,
DDKDLTNLTSSRPLAA; Chlamydia trachomatis (CTR) 133–148,
ADKDLLQLVSSRVSVF; hepatitis C virus (HEC) 192–207, PEPDVVVLTSMLTDPS; Paracoccidioides brasiliensis (PAB) 1–16, MDGDVLRETSSRLSGG; bovine ribonuclease (RNase) 43–56, VNTFVHESLADVQA; N-terminal biotinylated hen egg white lysozyme
(HEL) 46–61, YNTDGSTDYGILQINSR; and three APLs, designated
with subscript ‘AP’ and a number 1, 2 or 3: EHC 44–59AP1, HDKDVVVLASSRLSNR; EHC 44–59AP2, HDKDVAVLTSSRLSNR and EHC
44–59AP3, HDKDVVVLTSSRLSNR. All peptides were HPLC-purified (> 90%), confirmed by mass spectroscopy and dissolved in sterile 1 × PBS prior to use.

2.1. Mice

2.4. Immunization procedures

Six- to eight-week-old female, A/J mice carrying the H-2a allele IAk at the major histocompatibility complex (MHC) class II locus were procured from Jackson Laboratory (Bar Harbor, ME). The
animals were maintained in accordance with the animal protocol
guidelines of the University of Nebraska-Lincoln, Lincoln, NE.

To measure recall responses, peptides were emulsified in complete Freund’s adjuvant (CFA) and administered s.c. (50 μg/mouse)
in the inguinal and sternal regions and foot-pads (Massilamany et
al., 2011a, 2011b). For disease induction, peptides were emulsified
in CFA supplemented with Mycobacterium tuberculosis H37RA extract (Difco Laboratories, Detroit, MI) to a final concentration of
5 mg/ml, and the emulsions were administered at indicated doses
s.c. in the inguinal and sternal regions and base of the tail. Additionally, pertussis toxin (PT; List Biological Laboratories, Campbell, CA) was administered i.p. at indicated doses on day 0 and day 2
postimmunization ( Silver et al., 1995; Namba et al., 1998).

2.2. Identification of mimicry epitopes for IRBP 201–216
We used bovine IRBP 201–216 (ADKDVVVLTSSRTGGV) as
a disease-inducing retinal antigen (Caspi, 2003), in which the putative MHC class II- and T cell receptor (TCR)-binding sites have
been identified (Figure 1; Namba et al., 1998). Using this sequence,
we performed pattern searches using the prosite scan of the Bioinformatics Toolkit (http://toolkit.tuebingen.mpg.de/patsearch,
Max-Planck Institute for Developmental Biology, Tuebingen, Germany). The pattern used was XDXDXXXXXSXXXXXX (underlined:
TCR-contact residue; bold: MHC-anchor residues; X: non-critical
residues).

2.5. T cell proliferation assay
Groups of A/J mice were immunized with the indicated peptides, and at termination on day 10 or day 21, the animals were euthanized, and the draining lymph nodes (LN) were harvested to
prepare single cell suspensions (Massilamany et al., 2011b). Lymph
node cells (LNC) were stimulated with the indicated peptides (0–
100 μg/ml) at a density of 5 × 106 cells/ml for two days in growth
medium containing 1 × RPMI medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 4 mM l-glutamine, 1 ×
each of non-essential amino acids and vitamin mixture, and 100 U/
ml penicillin–streptomycin (Lonza, Walkersville, MD). Cultures
were then pulsed with 1 μCi of tritiated 3[H] thymidine/well (MP
Biomedicals, Santa Ana, CA); 16 h later, the proliferative responses
were measured as counts per minute (cpm) using a Wallac liquid
scintillation counter (PerkinElmer, Waltham, MA; Massilamany et
al., 2011a; Gangaplara et al., 2012).
2.6. IAk-binding assay

Figure 1. Comparison of microbial peptide sequences with IRBP 201–216.
The peptide sequence of IRBP 201–216 was compared with the mimicry epitopes derived from various microbes. IRBP, Interphotoreceptor retinoidbinding protein; EHC, Ehrlichia canis; PSP, Pseudomonas putida; TRC, Trypanosoma cruzi; CLN, Clostridium novyi; CTR, Chlamydia trachomatis; HEC,
hepatitis C virus; PAB, Paracoccidoides brasiliensis. Putative TCR- and MHCbinding residues are shown, respectively, with top and bottom arrows. Identical residues are underlined, and the numbers in parentheses indicate the
percent sequence identities with IRBP 201–216.

To determine the affinities of peptides binding to IAk, we used
soluble IAk molecules expressed in baculovirus as we have described
previously (Massilamany et al., 2011a, 2011b). Briefly, IAk constructs representing the extracellular domains of IAk-α and IAk-β
were designed, in which the sequence of class II-associated invariant-chain peptide (CLIP) 88–102 (VSQMRMATPLLMRPM) was
tethered into the N-terminus of the IAk-β construct, followed by introduction of a thrombin cleavage site to facilitate the release of the
CLIP peptide. Soluble IAk molecules were expressed in baculovirus
using sf9 insect cells, purified on an anti-IAk affinity column (clone,
10–2.16; BioXcell, West Lebanon, NH) and cleaved with thrombin
to obtain empty IAk molecules (Day et al., 2003; Massilamany et al.,
2011b). Cocktails of individual reaction mixtures were prepared to
include thrombin-cleaved IAk monomers (0.35 μg), competitor peptides [IRBP 201–216 or EHC 44–59 (0.000005 μM to 50 μM)] or al-
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tered peptides of EHC 44–59 (0.00001 μM to 100 μM), and a constant amount of biotinylated reference peptide, HEL 46–61 (1 μM),
in a buffer containing 50 mM sodium phosphate pH 7.0, 100 mM
sodium chloride, 1 mM EDTA, and 1 × protease inhibitor (SigmaAldrich, St. Louis, MO; Hausmann et al., 1999; Massilamany et al.,
2011b). The mixtures were incubated at room temperature (RT)
overnight. In parallel, anti-IAk (10 μg/ml) was coated onto 96-well
white fluorescence plates (Nunc, Rochester, NY) in sodium phosphate buffer 0.2 M, pH 6.8 overnight. Plates were washed five times
with 1 × wash buffer (PerkinElmer) and blocked with 2% casein for
2 h at 37 °C. After washing, the reaction mixtures described above
were added in duplicate for each peptide and incubated on a rocker
at RT for 1 h and washed. Europium-labeled streptavidin (SA) was
then added to a concentration of 1 μg/ml in dissociation-enhanced
lanthanide fluoroimmunoassay (DELFIA) buffer, followed by DELFIA-enhancement solution (PerkinElmer). Fluorescence intensities
were measured at excitation/emission wavelengths of 340/615 nm
using a Victor Multi Label Plate Reader (PerkinElmer). Concentrations of competitor peptides that prevented 50% binding of the
reference peptide (HEL 46–61) were taken as the half maximal inhibitory concentration (IC50) for each peptide (Hausmann et al.,
1999; Massilamany et al., 2011b).
2.7. Enumeration of the frequencies of antigen-specific
CD4 T cells by MHC class II/IAk tetramer staining
To determine the frequency of antigen-specific cells, LNC were
obtained from mice immunized with IRBP 201–216 or EHC 44–59,
and the cells were stimulated with the indicated peptides (50 μg/
ml) for two days and maintained in growth medium containing interleukin (IL)-2 (eBioscience, San Diego, CA; Advanced Biotechnologies, Columbia, MD). Viable lymphoblasts were harvested on day 5
by Ficoll-Hypaque density gradient centrifugation, washed twice using 1 × PBS to remove antigens; the cultures then were maintained
in growth medium containing IL-2. On day 9, cells were stained
with IAk/tetramers, anti-CD4 (eBioscience), and 7-aminoactinomycin D (7-AAD; Invitrogen, Carlsbad, CA) as we have previously described (Massilamany et al., 2010, 2011a). After acquiring the cells
by flow cytometry (FACSCalibur, BD Biosciences, San Diego, CA),
percentages of tetramer positive (tet+) cells were determined in the
live (7-AAD−) CD4+ subset using FlowJo software (Tree Star, Ashland, OR).
2.8. Intracellular cytokine staining
Groups of mice were immunized with the indicated peptides.
At termination, draining LNs were harvested to prepare singlecell suspensions. Cells were stimulated with the corresponding
peptides (50 μg/ml) for two days and maintained in growth medium containing IL-2. On day 5 poststimulation, viable lymphoblasts were harvested by Ficoll-Hypaque density gradient centrifugation and washed twice using 1 × PBS to remove antigen. Cells
were then stimulated with phorbol 12-myristate-13 acetate (PMA,
10 ng/ml) and ionomycin (150 ng/ml; Sigma-Aldrich) for five hours
in the presence of 2 mM monensin (GolgiStop, BD Pharmingen, San
Diego, CA; Gangaplara et al., 2012; Massilamany et al., 2009). After staining with anti-CD4 and 7-AAD, cells were fixed, permeabilized and stained with anti-cytokine antibodies along with their respective isotype controls (eBioscience). The cells were then acquired
by flow cytometry, and the frequencies of cytokine-producing cells
were determined in the live (7-AAD−) CD4+ subset. The clones of cytokine antibodies used were: IL-2 (JES6-5H4); interferon (IFN)-γ
(XMG1.2); IL-4 (11B11); IL-10 (JES5-16E3); IL-17A (eBio 17B7);
and IL-17 F (eBio 18F10) (all from eBioscience).
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2.9. Histopathology
At termination, the animals were euthanized and eyes were harvested. The freshly enucleated eyes were fixed in Davidson’s stock
solution containing 10% phosphate-buffered formalin and 90% ethanol (Fisher Scientific, Pittsburgh, PA), and the eyes were cross-sectioned at a thickness of 5 μm and stained by hematoxylin and eosin (H and E) staining (Silver et al., 1995; Namba et al., 1998). Eyes
were evaluated for inflammation by counting the foci in both eyes
corresponding to the corneal–scleral junction, iris, cornea, choroid
and retina; the counts were then added. Based on the morphology
of infiltrating cells, inflammation was classified as neutrophilic,
lymphocytic or mixed.
Table 1. Peptide sequences that mimic IRBP 201–216.
Source

Sequencea

IRBP 201–216
Bacteria
Brevibacterium linens BL2
Ehrlichia canis str. Jake
Catenulispora acidiphila DSM 44928
Shewanella halifaxensis HAW-EB4
Pyrococcus horikoshii OT3
Clostridium novyi NT
Chlamydia trachomatis 434/Bu
Pseudomonas aeruginosa UCBPP-PA14
Burkholderia phytofirmans PsJN
Vibrio parahaemolyticus 16
Salmonella enterica subsp.
enterica serovar Typhi str. CT18
Metallosphaera sedula DSM 5348
Citrobacter koseri ATCC BAA-895
Salmonella enterica subsp.  	
enterica serovar Typhi str. E02-1180
Salmonella enterica subsp. enterica
serovar Paratyphi C strain RKS4594
Citrobacter sp. 30_2
Citrobacter youngae ATCC 29220
Pseudomonas putida KT2440
Mycobacterium smegmatis str. MC2 155
Burkholderia pseudomallei 9
Helicobacter bilis ATCC 43879
Pseudomonas syringae pv. syringae B728a
Rhodopseudomonas palustris TIE-1
Rhodopseudomonas palustris HaA2
Rhodococcus jostii RHA1
Cyanobium sp. PCC 7001
Acidobacterium capsulatum ATCC 51196
Rhodococcus erythropolis PR4
Rhodococcus opacus B4
Kingella kingae
Fungi
Schizosaccharomyces japonicus yFS275
Paracoccidioides brasiliensis Pb18
Aspergillus niger
Magnaporthe grisea 70-15
Sclerotinia sclerotiorum 1980
Malassezia globosa CBS 7966
Ajellomyces capsulatus NAm1
Algae
Ostreococcus lucimarinus CCE9901
Chlamydomonas reinhardtii
Phaeodactylum tricornutum CCAP 1055/1
Guillardia theta
Protozoa
Dictyostelium discoideum AX4
Trypanosoma cruzi strain CL Brener
Leishmania braziliensis
MHOM/BR/75/M2904
Viruses
Hepatitis C virus
Helminths
Brugia malayi
Others
Strongylocentrotus purpuratus
(sea urchin)
Trichoplax adhaerens (metazoan)

ADKDVVVLTSSRTGGV

a. Identical residues are underlined.

Identity (%)

ADKDVKWLTRERTTGT
HDKDVAVLASSRLSNR
PDGDVVVLTSKDFEGL
ADIARKALTSSRTIIV
ADLDVVIATSRRGVDV
DDKDLTNLTSSRPLAA
ADKDLLQLVSSRVSVF
KDYDVVYATSSRLMTA
ADVDVSPLTSERAMAL
EDYDVVFATSSRLFTA
KGADVVVLTSGQTENK

62.5
56.25
56.25
56.25
56.25
50
50
50
50
50
50

CSVDVVVLTSSLIAKS
KGADVVVLTSGQTDNK
KGADVVVLTSGQTENK

50
50
50

KGADVVVLTSGQTENK

50

KGADVVVLTSGQTDNK
KGADVVVLTSGQTDNK
ADADALVLTRERTRID
ADGDDHRLTGSRTLVS
ADGAIGVLTLSRTQDP
RDKDAYNLISSRLKPI
PDVDVSLVTSERTHSM
ADPDVLRMTSLRAHDQ
DARDVVVLTSRPAQLS
NIMDVVVLTSVLSCLN
NHADVVVLTSPAQYPA
EGSDVVVLTSDNPRSE
NIMDVVVLTSVLSCLN
NIMDVVVLTSVLSCLN
ADADLSELTIERTAQG

50
50
50
50
50
43.75
43.75
43.75
43.75
43.75
43.75
43.75
43.75
43.75
43.75

DDKDFSVLHSSRLRSM
MDGDVLRETSSRLSGG
KDKDGNYLLSSRHFST
GDDDVFVDTSTRSPLP
DDEDVEFFTSKRQRKV
LDVDVPIETSERTAFT
ADKDLNINKSSRPSKA

50
50
43.75
43.75
43.75
43.75
43.75

ADGKSVDLTISRTGED
FDKDMQELTSSRRILD
ADEDAVGLTQRRTTTA
ADPELLKLTSDRTLFE

56.25
50
50
43.75

ADKKNSTLTSSRGNNK
DDSDVVVLTSENVEKS
ADKDDPLALSSRSPML

50
50
43.75

PEPDVVVLTSMLTDPS

50

SDSDVEAATSSRKRKT

43.75

IDLDVVVLTSSGNDRR

56.25

EDKDNQLLASSRRFAQ

43.75
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2.10. Statistics
Differences in T cell proliferative responses, IAk-binding affinities and cytokine analysis were determined using Student’s t-test.
p ≤ 0.05 values were considered significant. Stimulation indices indicated as ‘fold increase’ were calculated using the following formula: cpm values obtained in peptide-stimulated cultures / cpm values obtained in medium control.
3. Results
3.1. Identification of mimicry epitopes for IRBP 201–216
IRBP is recognized as one of the candidate retinal antigens in
EAU pathogenesis (Agarwal et al., 2012), and we used IRBP 201–
216 to identify mimicry sequences for two reasons: 1) IRBP 201–
216 induces EAU in susceptible mouse strains like A/J mice by
generating IRBP-reactive T cells (Caspi, 2003); and 2) its putative
MHC class II (IAk)- and TCR-contact residues have been identified
(Namba et al., 1998). While aspartic acid (Asp) at position 202 and
serine (Ser) at 210 are predicted to anchor the IAk molecule, Asp at
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position 204 is supposedly a TCR-contact residue (Figure 1; Namba
et al., 1998). In our search, we kept these residues constant, with
an expectation that the mimicry epitopes bearing the critical MHCand TCR-contact residues should be able to induce cross-reactive T
cell responses for IRBP 201–216. This analysis led us to identify 48
sequences – belonging to various microbes such as bacteria, viruses,
fungi, algae, protozoa and helminths, including two marine organisms – that show a similarity of 43.75 to 62.5% with IRBP 201–216
(Table 1). We chose a panel of seven of these mimics from microbes
that have been implicated in various eye diseases for further testing
(Figure 1). All the epitopes, except the viral mimic HEC 192–207,
contained both MHC- and TCR-contact residues, making them ideal
candidates to test for their immunogenicity.
3.2. T cells sensitized with IRBP 201–216 and EHC 44–59
cross-react with each peptide
Using T cell proliferation assay based on 3[H] thymidine incorporation, we first verified whether IRBP-reactive T cells can respond to mimicry epitopes by cross-reactivity. Briefly, LNC were
isolated from mice immunized with IRBP 201–216, and the re-

Figure 2. EHC 44–59 induces cross-reactive T cells for IRBP 201–216. A. T cell proliferation. Six- to eight-week-old female A/J mice were immunized with
IRBP 201–216 or EHC 44–59 in CFA. After 10 days, mice were sacrificed, the draining LN were harvested and single-cell suspensions were prepared. LNC were
stimulated with the indicated peptides for two days followed by pulsing with 3[H] thymidine. Proliferative responses were measured 16 h later as cpm. RNase
43–56, control. Mean ± SEM values obtained from three individual experiments involving 3–4 mice in each are shown. B. IAk-binding. The reaction mixtures
containing thrombin-cleaved IAk monomers (0.35 μg), competitor peptides (IRBP 201–216 or EHC 44–59: 0.000005 μM to 50 μM) and biotinylated HEL 46–
61 (1 μM) were individually prepared and added in duplicate to fluorescence plates coated with anti-IAk. After washing and addition of europium-labeled SA
and DELFIA-enhancer, fluorescence intensities were measured at excitation/emission wavelengths of 340/615 nm, and IC50 values were then calculated. Representative data sets (mean ± SEM values) from three to four individual experiments with two replicates in each are shown.

102
call responses were tested by stimulating the cells with IRBP and
its mimicry epitopes (Figure 1). Figure 2A (left panel) shows that
IRBP 201–216-sensitized LNC responded to IRBP 201–216 dose dependently as expected, and the response was specific because the
cells did not respond to RNase 43–56 (control). Likewise, a proportion of IRBP-reactive cells also reacted to EHC 44–59 (1.6-fold,
p = 0.007) when compared with the medium controls. Under similar conditions, the T cell responses for other mimics were found
to be not more than one-fold (data not shown). Hence, we focused
only on EHC 44–59 to determine its ability to induce cross-reactive
T cells for IRBP 201–216. As indicated in Figure 2A (right panel),
the animals immunized with EHC 44–59 showed strong proliferative responses to EHC 44–59, suggesting that the peptide is immunogenic. Similarly, a fraction of EHC 44–59-sensitized LNC also
responded to IRBP 201–216 (2-fold). The data suggest that cross-reactive T cells are induced by each peptide. Finally, we asked whether
EHC 44–59 can bind MHC class II/IAk molecules by establishing
IAk-binding assay (Massilamany et al., 2011b). Using HEL 46–61 as
a reference epitope, we ascertained that the IAk-binding affinities of
both IRBP 201–216 and EHC 44–59 were comparable (IC50 values:

Figure 3. Cross-reactive T cells induced by IRBP 201–216 and EHC 44–59
are antigen specific. Groups of A/J mice were immunized with IRBP 201–
216 or EHC 44–59 in CFA. Ten days later, animals were killed and LN were
harvested to prepare single cell suspensions. LNC were stimulated with peptides for two days, and the cells were maintained in growth medium containing IL-2 for a week. Viable lymphoblasts were harvested on day 9 poststimulation and stained with IAk/tetramers, anti-CD4 and 7-AAD. After
acquiring the cells by flow cytometry, tet+ cells were analyzed in the live (7AAD−) CD4 subset using FlowJo software. RNase 43–56, control. Representative flow cytometric dot plots from three individual experiments involving
3 to 4 mice in each are shown.
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12.04 ± 2.14 vs. 15.52 ± 3.61 μM; Figure 2B). Thus, we identified
EHC 44–59 as a candidate mimicry epitope for IRBP 201–216.
3.3. Cross-reactive T cell responses induced by IRBP 201–216
and EHC 44–59 are antigen-specific
To determine the antigen specificity of CD4 T cell responses induced by IRBP 201–216 and EHC 44–59, we created MHC class II/
IAk tetramers based on a peptide exchange reaction (Massilamany
et al., 2011a). Briefly, soluble IAk monomers containing CLIP 88–
102 were initially expressed in the baculovirus, and after cleaving
the CLIP peptide, empty IAk molecules were derived, into which
IRBP 201–216, EHC 44–59 or RNase 43–56 (control) peptides were
loaded exogenously. The IAk-peptide complexes were then multimerized to derive tetramers. Antigen-sensitized LNC cultures were
derived from mice immunized with IRBP 201–216 or EHC 44–59,
and the cells were stained with IAk/tetramers. As expected, CD4
T cells sensitized with IRBP 201–216 bound to IRBP tetramers
(1.42%; Figure 3, top left panel); some also bound to EHC tetramers (0.52%; Figure 3, middle left panel). Similar results were obtained when EHC 44–59-sensitized CD4 T cells were stained with
EHC tetramers (3.06%; Figure 3, middle right panel) and IRBP tetramers (0.40%; Figure 3, top right panel). The binding of IRBP 201–
216 or EHC 44–59 tetramers was specific, since the staining intensities obtained with the control tetramers (RNase 43–56) were low
(~ 0.15%; Figure 3, lower panels). The data suggest that the T cells
sensitized with IRBP 201–216 or EHC 44–59 can cross-react with
each epitope with specificity.

Figure 4. IRBP 201–216 and EHC 44–59 induce identical pattern of cytokines. A. Intracellular cytokine staining. A/J mice were immunized with the
indicated peptides in CFA. Ten days later, animals were killed and LN were
harvested to prepare single cell suspensions. LNC were stimulated with peptides for two days, and the cells were maintained in growth medium containing IL-2. Viable lymphoblasts were harvested on day 5 poststimulation and
stimulated with PMA and ionomycin in the presence of GolgiStop for five
hours. After fixation and permeabilization, cells were stained with a panel of
antibodies for Th1, Th2 and Th17 cytokines, followed by staining with antiCD4 and 7-AAD. After acquiring the cells by flow cytometry, cytokine-positive cells were analyzed in the live (7-AAD−) CD4 subset. Mean ± SEM values derived from three individual experiments involving 3 to 4 mice in each
are shown. B. Cytokine ELISA. Culture supernatants harvested from the
above cultures on day 2 poststimulation were analyzed by cytokine ELISA.
Mean ± SEM values representing three to four individual experiments with
two duplicates for each are shown.
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Figure 5. EHC 44–59 failed to induce uveoretinitis in A/J mice. Six- to eight-week-old mice were immunized with IRBP 201–216 or EHC 44–59 (50 μg/mouse) in
CFA. PT (100 ng/mouse), was administered intraperitoneally on days 0 and 2 postimmunization. At termination on day 21, the animals were euthanized, and eyes
were collected for histological evaluation of inflammation. Note lymphocytic infiltrations in iris (A), corneal–scleral junction (B) and retina (C) in animals immunized with IRBP 201–216 and absence of infiltrates in EHC 44–59-immunized animals (D and E) (arrows: infiltrates). Original magnification, × 40 (bar = 20 μm).
Representative data from three to five individual experiments each involving 5 to 9 mice are shown.

3.4. T cells sensitized with IRBP 201–216 or EHC 44–59 produce
comparable cytokines
One of the hallmarks of autoreactive T cells is their ability to produce cytokines of Th1 and Th17 phenotypes that favor autoimmunity, including EAU (Damsker et al., 2010; Horai and Caspi, 2011).
Therefore, we performed cytokine analysis by intracellular cytokine
staining and ELISA for a panel of Th1 (IL-2 and IFN-γ), Th2 (IL-4
and IL-10) and Th17 (IL-17A and IL-17F) cytokines. Enumeration of
the frequencies of cytokine-producing CD4 T cells in LNC cultures
specific to IRBP 201–216 or EHC 44–59 revealed that the cells capable of producing all of the cytokines tested were present (Figure 4).
By analyzing the ratios between the frequencies of Th1-, Th17- and
Th2-cytokine producing cells, we noted that a greater percentage of
CD4 T cells was positive for Th1 and Th17 than for Th2 cytokines
in cultures stimulated with both IRBP 201–216 (p ≤ 0.02) and EHC
44–59 (Figure 4A). We verified these results by cytokine ELISA using culture supernatants, and the patterns were reproduced for both
peptides (Figure 4B; p ≤ 0.03). The finding that EHC 44–59-responsive cells produced cytokines comparable to those produced by IRBP
201–216-responsive cells raised the possibility that EHC 44–59 may
be able to induce EAU in immunized animals.
3.5. EHC 44–59 lacks the ability to induce uveoretinitis
To ascertain the disease-inducing ability of EHC 44–59, we
first established a positive control system by optimizing the dose
for IRBP 201–216 to induce EAU in immunized animals. Histo-

logically, the infiltrates were predominantly comprised of lymphocytes and a few neutrophils. Doses of IRBP 201–216 up to 50 μg/
animal induced comparable histologic EAU, and the inflammatory foci tended to be found more in the corneal–scleral junction,
iris and ciliary body than in the choroid, cornea and retina (mean
foci ± SEM, 7.75 ± 2.97; Table 2; Figure 5A, B, and C). In contrast,
none of the animals immunized with EHC 44–59 showed any evidence of inflammation (Figure 5D and E). This negative disease phenotype could not be altered by increasing PT even up to 1000 ng/
animal (Namba et al., 1998; Silver et al., 1999) nor by immunizing the animals twice (Massilamany et al., 2011b; data not shown).
Thus, we concluded that EHC 44–59 can generate cross-reactive T
cells for IRBP capable of producing Th1 and Th17 cytokines, but it
lacks uveitogenicity.
3.6. EHC 44–59 prevents EAU induced with IRBP 201–216
We investigated whether the inability of EHC 44–59 to induce
EAU may be due to low frequencies of IRBP-reactive T cells generated in immunized animals. To address this possibility, we first immunized groups of animals with a suboptimal dose (10 μg) of IRBP
201–216; one group of animals was subsequently immunized with
EHC 44–59 seven days later, and at termination on day 21, eyes were
evaluated for histologic disease. While the animals immunized with
IRBP 201–216 alone (5/13 = 38.5%) had inflammatory foci in the
eyes [Figure 6A (i) and A (ii)], none of the IRBP 201–216-primed/
EHC 44–59-immunized animals (n = 9) showed inflammation [Figure 6A (iii)]. To determine whether this lack of disease was due to

Table 2. Histological EAU induced with IRBP 201–216 and EHC 44–59 in A/J mice.
Number of foci (mean ± SEM)
Peptide
IRBP 201–216
EHC 44–59

Dose (μg)
50
50
100

Incidence (%)
9/20 (45)
0/21 (0)
0/6 (0)

Corneal–scleral junction
2.6 ± 0.89
0
0

Total foci (mean ± SEM)

Iris

Cornea

4.25 ±1.93
0
0

0.3 ± 0.22
0
0

Choroid

Retina

0.45 ±0.28 0.15 ±0.15
0		
0
0		0

7.75 ±2.97
0
0

104
competition between IRBP 201–216 and EHC 44–59 for binding to
MHC molecules, we immunized IRBP 201–216-primed animals with
a control peptide (RNase 43–56). In this setting, we did observe infiltrates [2/4 = 50%; Figure 6A (iv)], suggesting that competition for
MHC between peptides would not have accounted for lack of disease
in animals immunized with IRBP and EHC peptides.
We next confirmed that the lack of EAU induction is not due
to the absence of IRBP-reactive T cells. As shown in Figure 6B (left
panel), the animals primed with IRBP 201–216 showed good proliferative responses to IRBP 201–216 (4.93-fold, p = 6.56E− 06)
as compared to those in the medium controls, but the response to

Figure 6. EHC 44–59 prevents development of uveoretinitis induced by
IRBP 201–216. A. Histological EAU. Groups of mice were immunized with
suboptimal doses of IRBP 201–216 (10 μg/mouse) seven days prior to immunization with or without EHC 44–59 or RNase 43–56 (100 μg/mouse) in
CFA, and PT (500 ng/mouse) was administered on day 0 and day 2 after the
first immunization. At termination on day 21, eyes were collected for histological evaluation of inflammation. Note scleral and posterior chamber lymphocytic infiltrates in animals immunized with the suboptimal dose of IRBP
201–216 [(i) and (ii)]; normal sclera and ciliary body in animals primed with
IRBP 201–216 and later immunized later with EHC 44–59 (iii); and presence
of infiltrates in the corneal–scleral junction in animals primed with IRBP
201–216 and subsequently immunized with control peptide (RNase 43–56)
(iv). Original magnification, × 40 (bar = 20 μm). Representative data from
three individual experiments, each involving 4 to 5 mice, are shown. B. T cell
proliferation. LNC harvested from the above groups were stimulated with
the indicated peptides for two days followed by pulsing with 3[H] thymidine.
Proliferative responses were measured 16 h later as cpm. RNase 43–56, control. Mean ± SEM values derived from representative experiment from three
individual experiments, each involving 4 to 5 mice, are shown.
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EHC 44–59 was low (1.84-fold, p = 0.0033). In contrast, LNC obtained from IRBP 201–216-primed/EHC 44–59-immunized animals
responded comparably to both the peptides (IRBP 201–216: 3.4fold, p = 0.0005; EHC 44–59: 3.6-fold, p = 0.0001; Figure 6B, right
panel), indicating that their responses were amplified in response to
EHC 44–59-immunization. The data suggest that IRBP-sensitized T
cells can expand to a significant proportion in response to EHC 44–
59, but the lack of EAU induction in IRBP-primed/EHC-immunized
animals raises a question whether EHC 44–59 can behave as a disease-suppressing natural APL.
3.7. Altered EHC 44–59 can induce uveoretinitis
To address the possibility that EHC 44–59 can act as an APL,
we chose to alter the peptide sequence by substituting the residues
within the core region of EHC 44–59, thereby increasing the identity with IRBP 201–216. As indicated in Figure 7A, the region spanning amino acids 45 to 55 contains putative MHC- and TCR-contact
residues similar to those in IRBP 201–216. This region of EHC 44–
59 is also identical to the same region in IRBP 201–216, except that
alanine (Ala) occurs at positions 49 and 52, corresponding to positions 206 and 209 in IRBP 201–216, which contain valine and threonine, respectively. We targeted these residues to generate APLs. In
the first APL (EHC 44–59AP1), Ala at position 49 was substituted
with valine (Val); in the second (EHC 44–59AP2), Ala at position 52
was substituted with threonine (Thr); and in the third (EHC 44–
59AP3), Ala at both positions 49 and 52 were substituted with Val
and Thr, respectively (Figure 7A).
We verified the disease-inducing abilities of APLs by immunizing groups of mice (n = 10) and euthanizing animals after three
weeks to enucleate the eyes for histological evaluation of EAU. Figure 7B [top panels (i), (ii) and (iii)] shows that the mice immunized
with EHC 44–59AP1 had inflammatory foci in the sclera, cornea, ciliary body and posterior chamber (3/10 = 30%), and none of the mice
immunized with EHC 44–59AP2 or EHC 44–59AP3 had lesions (Figure 7B, bottom panels). We next examined whether these differential effects of APLs may be due to variations, if any, in the generation of IRBP-reactive T cells in response to APLs. As expected,
LNC from mice immunized with IRBP 201–216 responded to IRBP
201–216 with a 3.5-fold enhancement relative to the medium controls, but responses to APLs varied (Figure 7C, upper left panel) in
that the response to EHC 44–59AP1 was relatively higher (3.3-fold)
than responses to the other two APLs. Likewise, by testing the T
cell responses in mice immunized with APLs, we noted that LNC
from mice immunized with EHC 44–59AP1 responded well to both
the immunizing peptide and IRBP 201–216 (Figure 7C, upper right
panel). Such responses were low in animals immunized with EHC
44–59AP2 or EHC 44–59AP3 (Figure 7C, bottom panels). Similar differences also were noted with the cytokine analysis, where LNC cultures derived from mice immunized with EHC 44–59AP1 contained a
higher proportion of IFN-γ-producing Th1 cells than cultures from
mice immunized with EHC 44–59AP2 (p = 0.045) or EHC 44–59AP3
(p = 0.023; Figure 7D). Furthermore, by evaluating the IAk-binding affinities of APLs (Figure 8), we noted that EHC 44–59AP1 binds
much more strongly to IAk molecules (IC50: 4.14 ± 0.28 μM) than do
EHC 44–59AP2 (IC50: 9.35 ± 0.55 μM; p = 0.001) and EHC 44–59AP3
(IC50: 7.48 ± 0.38 μM; p = 0.002). This may be the reason EHC 44–
59AP1 has greater immunogenicity and disease-inducing ability than
the others. The fact that EHC 44–59 failed to induce EAU on its own
and one of its APLs (EHC 44–59AP1) induced EAU by preferentially
expanding IFN-γ-producing IRBP-reactive T cells further supported
the proposal that EHC 44–59 may act as a naturally occurring APL.
4. Discussion
We report here identification of a mimicry epitope from E. canis
for IRBP 201–216, which is recognized as one of the candidate ocular
antigens in EAU pathogenesis ( Silver et al., 1995; Namba et al., 1998;
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Figure 7. EHC 44–59AP1 – but not EHC 44–59AP2 and EHC 44–59AP3 – induces EAU. A. Comparison of sequences between IRBP 201–216 and altered EHC
peptides. Three altered peptides were generated for EHC 44–59, such that Ala at positions 49 and 52 was substituted with Val and Thr, respectively, in the
first (EHC 44–59AP1) and second peptides (EHC 44–59AP2), and both substitutions were made in the third peptide (EHC 44–59AP3). Identical residues are underlined, and the substituted residues are overlined. B. Histological EAU. Groups of mice were immunized with the indicated peptides (50 μg/mouse) in CFA,
and PT (500 ng/mouse) was administered intraperitoneally on days 0 and 2 postimmunization. At termination on day 21, eyes were enucleated for histological evaluation of inflammation. Note lymphocytic infiltrates at corneal–scleral junctions (i), iris (ii), and posterior chamber (iii) in animals immunized with
EHC 44–59AP1 (arrows), as opposed to normal sections in animals immunized with EHC 44–59AP2 or EHC 44–59AP3 (bottom panel). Original magnification,
× 40 (bar = 20 μm). Representative data from two individual experiments, each involving five mice, are shown. C. T cell proliferation. LNC generated from the
above groups were stimulated with the indicated peptides for two days, and, after pulsing with 3[H] thymidine, proliferative responses were measured as cpm.
Data sets from two experiments, each involving 5 to 8 mice, are shown. D. Intracellular cytokine staining. LNC were first stimulated with the indicated peptides for two days in growth medium, and IL-2 was then supplemented. On day 5, viable cells were stimulated with PMA/ionomycin in the presence of GolgiStop for five hours, and, after staining with anti-CD4 and 7-AAD, cells were fixed and permeabilized to stain with cytokine antibodies. Cells were then acquired
by flow cytometry, and the percent cytokine+ cells were enumerated in the live (7-AAD−) CD4 subset. Mean ± SEM values derived from two individual experiments, each involving 5 mice, are shown.

Cortes et al., 2008; Agarwal et al., 2012). Unexpectedly, instead of
functioning as a disease-inducing antigen, the mimicry epitope (EHC
44–59) prevented the disease induced with IRBP 201–216. We provide four lines of evidence to support this finding: 1) EHC 44–59 and
IRBP 201–216 contain identical discontinuous stretches of nine residues in which the putative MHC- and TCR-contact residues are localized (Figure 1); 2) T cell responses induced by EHC 44–59 crossreact with IRBP 201–216, and the antigen-sensitized T cells produce
predominantly Th1 and Th17 cytokines that promote organ-specific autoimmunity, including EAU (Figure 4; Luger et al., 2008; Yoshimura et al., 2009); 3) the mimicry epitope prevented the development of EAU in animals previously primed with IRBP 201–216, and
such an alteration in the disease phenotype was not due to the absence of IRBP-reactive T cells ( Figure 6); and 4) finally, one of the altered peptides of the mimicry epitope (EHC 44–59AP1) that shows a

resemblance to IRBP 201–216 induced EAU through the production
of IFN-γ-producing, IRBP-reactive T cells (Figure 7).
Uveitis is a sight-threatening disease that accounts for approximately 10% of severe vision loss (Agarwal et al., 2012), and autoimmune responses have been suspected in the disease mediation (Wildner and Diedrichs-Mohring, 2004; Levy et al., 2011; Agarwal et al.,
2012). To delineate the immune events of uveitis, various rodent
models of EAU have been developed, and the disease is induced by
immunizing the animals with ocular antigens or their peptide fragments (Caspi et al., 1988; Shinohara et al., 1990; Namba et al., 1998;
Caspi, 2003; Agarwal et al., 2012). Although it is difficult to recapitulate all events in animal models, histologic features of EAU resemble those of uveitis in humans. Thus, EAU models are commonly employed to study the immune pathogenesis of sight-threatening ocular
diseases such as sympathetic ophthalmia, Behcet’s disease, birdshot
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Figure 8. EHC 44–59AP1 binds more strongly than EHC 44–59AP2 and
EHC 44–59AP3 to IAk molecules. The reaction mixtures containing thrombin-cleaved IAk monomers (0.35 μg) and competitor APLs of EHC 44–59
(0.00001 μM to 100 μM) and biotinylated reference peptide HEL 46–61
(1 μM) were individually prepared and added in duplicate to fluorescence
plates coated with anti-IAk. After washing and addition of europium-labeled
SA and DELFIA-enhancer, fluorescence intensities were measured at excitation/emission wavelengths of 340/615 nm, and IC50 values were then calculated. Representative data sets (mean ± SEM values) from three individual
experiments with two replicates in each are shown.

retinochoroidopathy and Vogt–Koyanagi–Harada syndrome (Agarwal
et al., 2012). While rats are susceptible to EAU induced with both soluble antigen (also called arrestin) and IRBP, mice are susceptible to
only IRBP, and various uveitogenic epitopes of IRBP have been identified (Caspi et al., 1988; Caspi, 2003; Cortes et al., 2008; Agarwal et
al., 2012). One such epitope is IRBP 201–216, which is expected to
induce EAU with a relatively higher degree of severity in B10.A mice
than in A/J mice (Caspi, 2003), yet both strains possess a similar
MHC class II/IAk allele. However, in our hands, IRBP 201–216, in addition to being less immunogenic, induced EAU with less severity in
B10.A mice than in A/J mice (data not shown), leading us to use A/J
mice to test the uveitogenicity of mimicry epitopes in our studies.
Generally, exposure to mimicry sequences is expected to lead
to induction of pathogenic cross-reactive T cells or autoantibodies
(Singh et al., 1990; Shinohara et al., 1991; Rose, 2001, Fujinami et
al., 2006; Massilamany et al., 2011b). An exception to this paradigm
is the possibility that cross-reactive immune responses may not
lead to disease, as shown with a mimic from Haemophilus influenzae for myelin proteolipid protein 139–151 (Carrizosa et al., 1998).
Alternatively, although less commonly reported, mimicry epitopes
can act as APLs by suppressing diseases like experimental autoimmune encephalomyelitis induced with a cognate epitope, myelin basic protein 85–99 (Ruiz et al., 1999; Steinman et al., 2005; Maverakis et al., 2010). Our data with EHC 44–59 agree with the concept
that microbial mimics can act as APLs but provide new insights as
to their underlying mechanisms.
APLs are believed to act by ablating antigen-specific T cell responses or by deviating cytokine responses from a Th1 (disease-promoting) to a Th2 (disease-suppressing) phenotype and/or promoting
the generation of regulatory T cells (Paas-Rozner et al., 2001; Alleva
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et al., 2002; Aruna et al., 2006). In our studies with EHC 44–59, while
generation of antigen (IRBP 201–216)-specific T cell responses was
not altered, the EHC-responsive T cells produced both Th1 and Th17
cytokines similar to those produced by IRBP-reactive T cells. On the
contrary, production of Th2 cytokines contributed by IL-4 and IL-10
was not elevated. We further ruled out a possibility that differences,
if any, in the frequencies of IRBP-reactive T cells could account for
lack of disease induced with EHC 44–59 by immunizing the animals
primed previously with IRBP 201–216 (Figure 6). In this setting,
we noted that T cells specific to both antigens were present, leading
to the conclusion that EHC 44–59 did not selectively deplete IRBPspecific cells. However, recent studies indicate that APLs can inhibit
T cell activation by affecting phosphorylation of key T cell signaling
molecules, such as CD3ζ, CD3ε, Zap-70, src kinases, p56lck and p59fyn
(Madrenas et al., 1995; Sloan-Lancaster and Allen, 1996). But we did
not investigate these possibilities in our studies.
As additional evidence for a proposal that EHC 44–59 can act as
an APL, we altered the peptide sequence to more closely resemble
the cognate peptide IRBP 210–216 by changing two Ala residues individually or together. We noted that one peptide (EHC 44–59AP1)
that contained Val in place of Ala at position 49 was able to induce
EAU. EHC 44–59AP3 bearing two substitutions at positions 49 and
52 was expected to induce EAU, but this was not the case. Evidently,
the amount of IRBP-reactive T cells produced in response to this peptide was also low (Figure 7C, bottom right panel). Further, by cytokine analysis, we noted that the frequencies of IFN-γ-producing cells
were elevated only with the disease-inducing peptide EHC 44–59AP1
(Figure 7D). Numerous studies indicate that EAU induction requires
the mediation of both Th1 and Th17 cells (Xu et al., 1997, 2004; Peng
et al., 2007; Luger et al., 2008), but the disease can be induced in
C57Bl/6 mice deficient for IFN-γ or IL-17 with deviant or altered disease phenotypes (Caspi et al., 1994; Jones et al., 1997; Luger et al.,
2008; Yoshimura et al., 2008). Furthermore, IFN-γ appears to mediate multiple roles (disease-aggravating or disease-protective) in EAU
pathogenesis (Jones et al., 1997; Xu et al., 2004; Tang et al., 2007).
Whether such differential effects are dose dependent is not known.
Since EHC 44–59AP1 induced higher frequencies of IFN-γ-producing
IRBP-reactive T cells than two other altered peptides (EHC 44–59AP2
and EHC 44–59AP3), our data suggest that IFN-γ-producing cells may
have led to the disease mediation.
In summary, we have provided evidence that a mimicry epitope
derived from E. canis can act as a naturally occurring APL by suppressing the disease induced with IRBP 201–216 without altering
IRBP-specific T cell responses. To induce cross-reactive immune responses for microbes carrying mimicry epitopes, humans need not
be natural hosts. Conversely, the natural pathogens of humans carrying the mimicry epitopes can induce inflammation by generating
cross-reactive immune responses, but such responses can be detrimental to the survival of parasites. It may be that, evolutionarily,
coexistence of parasites with hosts may promote acquisition of the
host’s genetic material, and introduction of mutations under selection pressure may favor attenuation of the host’s immune response,
leading to their survival.
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